Avanos Medical Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $715.9M+4.1% YoYTTM through 31 Mar 2026
Net Income -$74.4MTTM through 31 Mar 2026
Free Cash Flow $7.5MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | 50.5% |
| EBITDA Margin | -3.3% |
| Operating Margin | -8.8% |
| Net Margin | -10.4% |
Returns
-9.4%ROE
-6.8%ROA
Balance Sheet Health
Debt / Equity0.13x
Current Ratio2.48x
Net Debt$10.7M
Cash & Equivalents$65.6M
Quality Metrics
Altman Z-Score2.29
Piotroski F-Score6 / 9
FCF Margin1.0%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $701.2M
Diluted EPS-$1.60TTMFY2025: $-1.57
Dividend
No dividend
Capital Allocation
R&D Spend$23.1M
Capex Intensity4.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Specialty Nutrition Systems (SNS) | $432.9M | +9.2% | View detailsSNS segment continues to deliver above-market results driven by strong demand across enteral feeding and neonate solutions, further strengthened by the Nexus Medical acquisition. |
| Pain Management and Recovery (PM&R) | $237.8M | +1.5% | View detailsPM&R segment operating income improved to $9.2 million in 2025 from $2.7 million in 2024, despite portfolio reshaping including the divestiture of the HA product line and Game Ready rental business. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.